For filings with the FCA include the annex |
|
||||
For filings with issuer exclude the annex |
|
||||
|
|||||
TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi |
|||||
|
|
||||
1. Identity of the issuer or the underlying issuer |
INTEGRATED DIAGNOSTICS HOLDINGS PLC |
||||
2 Reason for the notification (please tick the appropriate box or boxes): |
|||||
An acquisition or disposal of voting rights |
X |
||||
An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached |
|
||||
An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments |
|
||||
An event changing the breakdown of voting rights |
|
||||
Other (please specify): |
|
|
|||
3. Full name of person(s) subject to the |
T. Rowe Price Associates, Inc. |
||||
4. Full name of shareholder(s) |
JP Morgan Chase Bank of New York Mellon Bank, N.A. Northern Trust Co. |
||||
5. Date of the transaction and date on |
08 March 2017 |
||||
6. Date on which issuer notified: |
10 March 2017 |
||||
7. Threshold(s) that is/are crossed or |
5% |
||||
8. Notified details: |
||||||||||||||||
A: Voting rights attached to shares viii, ix |
||||||||||||||||
Class/type of
|
Situation previous |
Resulting situation after the triggering transaction |
||||||||||||||
Number |
Number |
Number |
Number of voting |
% of voting rights x |
||||||||||||
Direct |
Direct xi |
Indirect xii |
Direct |
Indirect |
||||||||||||
JE00BV9H9G76 |
7,474,850 |
7,474,850 |
7,570,134 |
|
7,570,134 |
|
5.04% |
|||||||||
|
||||||||||||||||
|
||||||||||||||||
B: Qualifying Financial Instruments |
||||||||||||||||
Resulting situation after the triggering transaction |
||||||||||||||||
Type of financial |
Expiration |
Exercise/ |
Number of voting |
% of voting |
||||||||||||
|
|
|
|
|
||||||||||||
|
||||||||||||||||
C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi |
||||||||||||||||
Resulting situation after the triggering transaction |
||||||||||||||||
Type of financial |
Exercise price |
Expiration date xvii |
Exercise/ |
Number of voting rights instrument refers to
|
% of voting rights xix, xx
|
|||||||||||
|
|
|
|
|
Nominal |
Delta |
||||||||||
|
|
|||||||||||||||
|
||||||||||||||||
Total (A+B+C) |
||||||||||||||||
Number of voting rights |
Percentage of voting rights |
|||||||||||||||
7,570,134 |
5.04% |
|||||||||||||||
9. Chain of controlled undertakings through which the voting rights and/or the |
||
T. Rowe Price Associates, Inc. (TRPA) serves as investment adviser, with dispositive and voting authority, to various institutional clients that own shares of Integrated Diagnostics Holding Plc., including the T. Rowe Price International Discovery Fund, which owns 5,391,836 shares. Such shares are registered in the following name(s):
Bank of New York Mellon Bank, N.A. - 337,429
JP Morgan Chase - 7,172,393
Northern Trust Co. - 60,312
|
||
|
||
Proxy Voting: |
||
10. Name of the proxy holder: |
|
|
11. Number of voting rights proxy holder will cease to hold: |
|
|
12. Date on which proxy holder will cease to hold voting rights: |
|
|
|
||
|
|
|
14. Contact name: |
Gary Greb, Vice President T. Rowe Price Associates, Inc. |
|
15. Contact telephone number: |
001 410 345 2527 |
|